FDA Outlines 2026 Medical Device Regulatory Guidance Priorities, Emphasizes Real-World Evidence and AI Software Oversight
核心洞察
The FDA has released its 2026 guidance priorities for medical devices, with top focus on finalizing real-world evidence standards and predetermined change control plans for regulatory decisions.
Four priority final guidance documents include diagnostics validation for emerging pathogens and patient preference information integration throughout product lifecycles.
The agency continues prioritizing draft guidance on air purifying respirators and menstrual products, with new emphasis on tampon safety following metal contamination concerns.
The Food and Drug Administration has unveiled its medical device guidance priorities for fiscal year 2026, signaling continued emphasis on real-world evidence integration and emerging technology oversight. The agency announced Tuesday that it will prioritize finalizing guidance on using real-world evidence to support regulatory decisions and predetermined change control plans for medical devices.
Priority Final Guidance Documents
The FDA's Center for Devices and Radiological Health (搜索) has identified four final guidance topics as top priorities for 2026. Beyond real-world evidence (RWE) and predetermined change control plans (PCCP), the agency will focus on finalizing guidance for validating diagnostics for emerging pathogens and incorporating voluntary patient preference information throughout the total product lifecycle.
Officials have conducted consultations on draft versions of all prioritized finalization documents. The real-world evidence guidance represents the longest-running project, with the FDA seeking feedback on a draft version in December 2023. The diagnostics document appeared on the agency's 2025 priority list, while patient preference guidance was previously developed as resources permitted.
Draft Guidance Development Priorities
Three of the FDA's four priority draft guidance documents carry over from the 2025 list. The agency continues prioritizing guidance on air purifying respirators and menstrual products, with the latter now focusing specifically on labeling and performance testing recommendations. This shift follows a study that raised concerns about potential health risks from metals in tampons.
A newly prioritized guidance addresses the FDA's policy for device software functions, representing a revision of existing 2022 guidance covering regulatory oversight of device software functions and mobile medical applications. This document was previously listed on the agency's B-list in 2025.
Resource-Dependent Guidance Development
Depending on available resources, the FDA may finalize up to three additional guidance documents from its B-list. These cover premarket considerations for weight loss devices, lifecycle management considerations and marketing submission recommendations for artificial intelligence-enabled software, and human factors information content in medical device marketing submissions.
Stakeholder Feedback and Implementation
The FDA is accepting feedback on the guidance list until December 1. Last year's feedback was "mostly in agreement" with the proposed priorities, according to the agency. The FDA indicated it will not develop four documents from its 2025 A-list, including two that would have addressed laboratory developed tests, an area where the agency recently revised its regulatory approach.
The guidance priorities reflect the FDA's continued focus on emerging technologies, patient safety, and evidence-based regulatory decision-making as medical device innovation accelerates across multiple therapeutic areas.